Hidroxiklorokin Meditop (Hydroxychloroquine Sulfate)

Hydroxychloroquine sulfate is indicated for several medical conditions where modulation of the immune system or antimalarial activity is required.

• Prevention and treatment of malaria caused by susceptible Plasmodium species.
• Management of rheumatoid arthritis as a disease‑modifying antirheumatic drug.
• Treatment of systemic lupus erythematosus to reduce disease activity.
• Control of cutaneous lupus and other dermatologic manifestations of autoimmune disease.
• Adjunctive therapy in selected autoimmune disorders when combined with other agents.

• Hydroxychloroquine increases the pH within lysosomes and endosomes, which interferes with antigen processing and presentation. By inhibiting Toll‑like receptor signaling, it reduces activation of dendritic cells and subsequent cytokine production, leading to a dampened immune response. These actions also impair the replication of malaria parasites that rely on acidic intracellular compartments, providing antimalarial effects.

Adverse reactions to hydroxychloroquine can vary in frequency and severity.

Common

• Nausea or vomiting
• Headache
• Abdominal discomfort or diarrhea
• Skin rash or pruritus
• Visual disturbances such as blurred vision
• Mild dizziness

Serious

• Retinal toxicity leading to irreversible vision loss
• Cardiomyopathy or conduction abnormalities
• Severe hypoglycemia, especially in diabetic patients
• Hematologic abnormalities (e.g., agranulocytosis, hemolytic anemia)
• Stevens‑Johnson syndrome or toxic epidermal necrolysis
• Neuropsychiatric events including seizures or mood changes

When prescribing hydroxychloroquine, clinicians should consider several safety measures.

• Obtain baseline ophthalmologic examination and schedule regular retinal monitoring.
• Perform periodic complete blood counts to detect hematologic effects.
• Assess cardiac function, especially in patients with pre‑existing heart disease.
• Avoid use in individuals with known hypersensitivity to the drug.
• Use caution during pregnancy and lactation; the safety profile is not well established.
• Adjust dosing in patients with significant renal or hepatic impairment.
• Do not discontinue abruptly without medical guidance.

Hydroxychloroquine may interact with other medicines, affecting its efficacy or safety.

Avoid

• Antacids containing aluminum or magnesium, which can reduce drug absorption.
• Other QT‑prolonging agents (e.g., quinidine, azithromycin) that increase the risk of cardiac arrhythmias.
• Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) that may raise hydroxychloroquine levels.
• Anticoagulants such as warfarin, which can have enhanced anticoagulant effects.
• Digoxin, due to potential increase in serum concentrations.

Use with caution

• Corticosteroids, as combined immunosuppression may be heightened.
• Other disease‑modifying antirheumatic drugs (e.g., methotrexate, sulfasalazine).
• Live attenuated vaccines, because immune response may be blunted.
• Insulin or oral hypoglycemics, due to additive hypoglycemic risk.
• Antiepileptic drugs that may alter seizure threshold.